Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease.
Weintraub D, Caspell-Garcia C, Simuni T, Cho HR, Coffey CS, Aarsland D, Alcalay RN, Barrett MJ, Chahine LM, Eberling J, Espay AJ, Hamilton J, Hawkins KA, Leverenz J, Litvan I, Richard I, Rosenthal LS, Siderowf A, York M; Parkinson’s Progression Markers Initiative. Weintraub D, et al. Among authors: eberling j. Ann Clin Transl Neurol. 2020 Apr;7(4):449-461. doi: 10.1002/acn3.51022. Epub 2020 Apr 13. Ann Clin Transl Neurol. 2020. PMID: 32285645 Free PMC article.
Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease.
Weintraub D, Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Siderowf A, Aarsland D, Barone P, Burn D, Chahine LM, Eberling J, Espay AJ, Foster ED, Leverenz JB, Litvan I, Richard I, Troyer MD, Hawkins KA; Parkinson's Progression Markers Initiative. Weintraub D, et al. Among authors: eberling j. Mov Disord. 2015 Jun;30(7):919-27. doi: 10.1002/mds.26170. Epub 2015 Mar 4. Mov Disord. 2015. PMID: 25737166 Free PMC article.
Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls.
Mollenhauer B, Caspell-Garcia CJ, Coffey CS, Taylor P, Shaw LM, Trojanowski JQ, Singleton A, Frasier M, Marek K, Galasko D; Parkinson's Progression Marker Initiative. Mollenhauer B, et al. Neurology. 2017 Nov 7;89(19):1959-1969. doi: 10.1212/WNL.0000000000004609. Epub 2017 Oct 13. Neurology. 2017. PMID: 29030452 Free PMC article.
Antemortem detection of Parkinson's disease pathology in peripheral biopsies using artificial intelligence.
Signaevsky M, Marami B, Prastawa M, Tabish N, Iida MA, Zhang XF, Sawyer M, Duran I, Koenigsberg DG, Bryce CH, Chahine LM, Mollenhauer B, Mosovsky S, Riley L, Dave KD, Eberling J, Coffey CS, Adler CH, Serrano GE, White CL 3rd, Koll J, Fernandez G, Zeineh J, Cordon-Cardo C, Beach TG, Crary JF. Signaevsky M, et al. Among authors: eberling j. Acta Neuropathol Commun. 2022 Feb 14;10(1):21. doi: 10.1186/s40478-022-01318-7. Acta Neuropathol Commun. 2022. PMID: 35164870 Free PMC article.
A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein.
Merchant KM, Cedarbaum JM, Brundin P, Dave KD, Eberling J, Espay AJ, Hutten SJ, Javidnia M, Luthman J, Maetzler W, Menalled L, Reimer AN, Stoessl AJ, Weiner DM; The Michael J. Fox Foundation Alpha Synuclein Clinical Path Working Group. Merchant KM, et al. Among authors: eberling j. J Parkinsons Dis. 2019;9(1):31-61. doi: 10.3233/JPD-181471. J Parkinsons Dis. 2019. PMID: 30400107 Free PMC article.
The Parkinson Progression Marker Initiative (PPMI).
Parkinson Progression Marker Initiative. Parkinson Progression Marker Initiative. Prog Neurobiol. 2011 Dec;95(4):629-35. doi: 10.1016/j.pneurobio.2011.09.005. Epub 2011 Sep 14. Prog Neurobiol. 2011. PMID: 21930184 Free PMC article. Review.
Safety and tolerability of putaminal AADC gene therapy for Parkinson disease.
Christine CW, Starr PA, Larson PS, Eberling JL, Jagust WJ, Hawkins RA, VanBrocklin HF, Wright JF, Bankiewicz KS, Aminoff MJ. Christine CW, et al. Among authors: eberling jl. Neurology. 2009 Nov 17;73(20):1662-9. doi: 10.1212/WNL.0b013e3181c29356. Epub 2009 Oct 14. Neurology. 2009. PMID: 19828868 Free PMC article. Clinical Trial.
78 results